PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTCT 12.17.2024

About Gravity Analytica
Recent News
- 01.13.2025 - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 01.13.2025 - 2025 J.P. Morgan Healthcare Conference
- 01.13.2025 - PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
Recent Filings
The inducement grants were approved by PTC's Compensation Committee on Dec. 13, 2024, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of $46.37 per share, the closing price of PTC's common stock on Dec. 13, 2024, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.
ABOUT
For more information please contact:
Investors:
Media:
View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302334077.html
SOURCE